Journal of Hepatocellular Carcinoma

Scope & Guideline

Pioneering insights into hepatocellular carcinoma treatments.

Introduction

Delve into the academic richness of Journal of Hepatocellular Carcinoma with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJ HEPATOCELL CARCINO / J. HEPATOCELL. CARCINOMA
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The Journal of Hepatocellular Carcinoma focuses on advancing the understanding and treatment of hepatocellular carcinoma (HCC) through innovative research methodologies and interdisciplinary approaches.
  1. Clinical Research and Trials:
    The journal publishes studies that investigate various clinical aspects of hepatocellular carcinoma, including treatment efficacy, patient outcomes, and therapeutic strategies across different patient demographics.
  2. Molecular and Genetic Studies:
    Research contributions often explore the molecular mechanisms underlying HCC, including genetic mutations, epigenetic modifications, and their implications for prognosis and treatment.
  3. Imaging and Radiomics:
    The journal emphasizes the role of advanced imaging techniques and radiomic analysis in predicting HCC progression, microvascular invasion, and treatment response.
  4. Immunotherapy and Targeted Therapies:
    A significant focus is placed on the development and clinical application of immunotherapeutic approaches and targeted therapies, particularly in combination with traditional treatments like transarterial chemoembolization.
  5. Biomarkers and Prognostic Models:
    Research on identifying novel biomarkers for early detection, prognosis, and treatment response prediction is a core area, aimed at enhancing personalized medicine in HCC.
  6. Public Health and Disparities:
    The journal also addresses healthcare disparities and the impact of socioeconomic factors on HCC treatment outcomes, contributing to a broader understanding of the disease in diverse populations.
The Journal of Hepatocellular Carcinoma is witnessing a dynamic evolution in its research focus, with several emerging themes gaining traction in recent years.
  1. Artificial Intelligence and Machine Learning:
    Recent publications increasingly utilize AI and machine learning techniques for predictive modeling, enhancing diagnostic accuracy, and personalizing treatment strategies for HCC patients.
  2. Combination Therapy Strategies:
    There is a growing trend towards exploring combination therapies, particularly integrating immunotherapy with traditional treatments, reflecting the need for more effective and comprehensive treatment regimens.
  3. Metabolic and Nutritional Factors:
    Research examining the role of metabolic syndrome, nutrition, and specific metabolic pathways in HCC progression and treatment response is emerging as a significant area of interest.
  4. Patient-Centered Care and Quality of Life:
    Studies focused on patient-reported outcomes, quality of life, and healthcare disparities are becoming more prominent, indicating a shift towards a more holistic approach to HCC management.
  5. Novel Biomarker Discovery:
    There is an increased emphasis on identifying and validating novel biomarkers for early detection and monitoring treatment response, driven by advances in genomic and proteomic technologies.

Declining or Waning

While the Journal of Hepatocellular Carcinoma continues to cover a wide range of topics, certain themes appear to be losing prominence in recent publications.
  1. Traditional Chemotherapy Approaches:
    Research focusing on conventional chemotherapy methods has decreased as newer targeted therapies and immunotherapies gain traction, reflecting a shift in treatment paradigms.
  2. Single-Modality Treatments:
    The emphasis on single-modality treatments, such as isolated surgical resection or standalone chemoembolization, is waning in favor of multimodal approaches that combine various therapies for improved outcomes.
  3. Basic Science without Clinical Application:
    There is a noticeable decline in studies that focus solely on basic science or laboratory findings without direct clinical relevance or application, as the journal increasingly prioritizes translational research.
  4. Epidemiological Studies:
    The frequency of purely epidemiological studies examining HCC incidence and prevalence is decreasing, possibly as the journal shifts towards more intervention-focused research.

Similar Journals

Clinical and Experimental Hepatology

Navigating the Complexities of Liver Health
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 2392-1099Frequency: 4 issues/year

Clinical and Experimental Hepatology is a pivotal journal dedicated to advancing the field of hepatology, providing a platform for researchers, clinicians, and students to disseminate and explore groundbreaking findings. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal serves as a vital resource for professionals seeking to enhance their knowledge and contributions in the realm of liver diseases and their management. With an impact factor reflective of its growing influence—ranking Q3 in Hepatology for the year 2023 and holding the 49th position out of 82 in Scopus Medicine Hepatology ranks—this publication underscores the significance of innovative research in this specialized domain. While it currently operates through a subscription model rather than open access, it bridges the gap in hepatological literature by featuring a diverse array of scholarly articles, case reports, and reviews from 2015 to 2024. Researchers and health professionals alike will find valuable insights that can enhance clinical practice and inform future studies, solidifying its importance in the hepatology community.

Hepatoma Research

Exploring New Horizons in Hepatoma Studies
Publisher: OAE PUBLISHING INCISSN: 2394-5079Frequency: 1 issue/year

Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.

Oncologie

Fostering dialogue in the dynamic world of oncology.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

HEPATOLOGY RESEARCH

Unveiling the complexities of liver health with cutting-edge research.
Publisher: WILEYISSN: 1386-6346Frequency: 12 issues/year

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

HEPATOLOGY

Advancing liver research for a healthier tomorrow.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0270-9139Frequency: 12 issues/year

HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.

Clinical and Molecular Hepatology

Transforming the landscape of hepatology with cutting-edge studies.
Publisher: KOREAN ASSOC STUDY LIVERISSN: 2287-2728Frequency: 4 issues/year

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

Nature Reviews Gastroenterology & Hepatology

Elevating Standards in Gastroenterology & Hepatology
Publisher: NATURE PORTFOLIOISSN: 1759-5045Frequency: 12 issues/year

Nature Reviews Gastroenterology & Hepatology is a premier academic journal published by NATURE PORTFOLIO, specializing in the vital fields of gastroenterology and hepatology. With an impressive impact factor and categorized in Q1 for both disciplines, this journal ranks at the top of its field, with Scopus rankings placing it in the 99th percentile for gastroenterology and hepatology. The journal aims to provide critical reviews that synthesize the latest research findings, clinical practices, and breakthroughs, catering to researchers, healthcare professionals, and students alike. With its wide-ranging access options, it promotes the dissemination of knowledge essential for advancements in understanding digestive and liver disorders. The journal has been committed to academic excellence since its convergence in 2009, continuing to shape the future of gastroenterological and hepatological research through rigorous peer-reviewed content.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Transforming Oncology with Innovative Research and Clinical Strategies.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Clinical Genitourinary Cancer

Advancing knowledge in genitourinary oncology.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

JTO Clinical and Research Reports

Empowering Global Collaboration in Cancer and Respiratory Research
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.